SLC5A2 and type 2 diabetes mellitus: We included people aged 18 years or older with T2DM who intensified to second‐line oral antidiabetic medication between 2014 and 2020 to investigate disparities in second‐line antidiabetic treatment prescribing (one of sulphonylureas [SUs], dipeptidyl peptidase‐4 [DPP‐4] inhibitors, or sodium‐glucose cotransporter‐2 [SGLT2] inhibitors, in combination with metformin) by ethnicity (White, South Asian, Black, mixed/other) and deprivation level (IMD quintiles).